Saturday 17 October 2026
Export SNYRQ’s income statement to Excel — free account
Synergy CHC Corp.
SNYRQ Healthcare Medical Distribution
Synergy CHC Corp.’s revenue for fiscal 2025 (year ended December 2025) was $30.4 million, down 12.8% from fiscal 2024. In the quarter to March 2026, revenue fell 32.8%, EPS fell 330.0%, free cash flow fell 148.5% and total debt rose 7.08%, each against the same quarter a year earlier.
0.00
0.01
−100.00%
Follow SNYRQ
| Older periods | Jun '25 | Sep '25 | Dec '25 | Mar '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
7.50 | 8.41 | 0.00 | 0.00 |
P/S ratio |
0.76 | 0.71 | 0.60 | 0.53 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(330.92) | (10.68) | 28.98 | (7.13) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.45 | 1.41 | 1.33 | 1.42 | |
EV/EBITDA |
6.94 | 6.52 | 0.00 | 0.00 | |
EV/Operating CF |
(10.74) | (7.36) | (15.67) | (10.33) | |
EV/FCF |
(10.74) | (7.36) | (15.67) | (10.33) | |
Quick Ratio |
2.12 | 3.79 | 0.72 | 0.24 | |
Current Ratio |
2.74 | 5.35 | 1.22 | 0.93 | |
Net Debt/EBITDA |
10.93 | 15.49 | (1.76) | 58.89 | |
Debt/Assets |
126.63% | 121.37% | 247.50% | 387.18% | |
Debt/Equity |
(2.02) | (3.04) | (1.09) | (0.98) | |
Asset Turnover |
2.18 | 2.11 | 2.29 | 2.51 | |
Operating CF/Net income |
(0.05) | (18.43) | (0.04) | 0.80 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.77 | 1.10 | (8.57) | (0.28) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
56.32% | 54.52% | 145.68% | 82.01% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.02 | |
Share Based Compensation of Revenue |
10.41% | 1.84% | 1.92% | 2.12% | |
Graham Net Nets |
(0.49) | (0.34) | (1.29) | (1.75) | |
Graham Number |
0.00 | 0.00 | 7.57 | 8.41 | |
Earnings Yield |
13.33% | 11.89% | (57.53%) | (108.53%) | |
Free Cash Flow Yield |
(17.93%) | (26.90%) | (14.29%) | (26.11%) | |
Revenue per Share |
0.91 | 0.79 | 0.62 | 0.49 | |
Operating CF per Share |
(0.01) | (0.23) | 0.06 | (0.18) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.01) | (0.23) | 0.06 | (0.18) | |
Cash per Share |
0.17 | 0.11 | 0.28 | 0.03 | |
Shareholders Equity per Share |
(1.39) | (0.82) | (2.38) | (2.25) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.39) | (0.82) | (2.38) | (2.25) | |
Free Cash Flow |
(0.08) | (2.31) | 0.62 | (2.04) | |
Working Capital |
12.38 | 16.68 | 1.78 | (0.50) | |
Net Current Asset Value |
(12.60) | (8.44) | (23.28) | (25.52) | |
EV/EBIT |
8.19 | 7.86 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
4.25 | 3.97 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.61 | 10.96 | 7.45 | 5.94 | |
Average Payables |
5.07 | 4.33 | 5.79 | 3.57 | |
Average Inventory |
2.14 | 2.03 | 2.73 | 2.86 | |
Average Assets |
15.48 | 16.43 | 13.25 | 11.06 | |
Average Common Equity |
(19.13) | (16.71) | (19.88) | (20.52) |
Columns are period end dates